Upstream Bio sets Phase 3 plans for verekitug in severe asthma and CRSwNP
Upstream Bio announced its pivotal Phase 3 development plans for verekitug, a drug candidate in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The company remains on track to start both trials in the first quarter of 2027 and says it could seek approval and launch as early as 2030 if results are supportive. The filing contains no financial results, so the update is a development milestone rather than a change in reported financial performance.
Key points
- Phase 3 plan: one placebo-controlled study in each indication, about 1,500 patients total, testing 400mg every 12 weeks
- Asthma primary endpoint: annualized asthma exacerbation rates over 48 weeks
- CRSwNP co-primary endpoints: change from baseline in nasal polyp score and nasal congestion score at 48 weeks
- Trials expected to start in Q1 2027; potential U.S. launch as early as 2030 if Phase 3 results are supportive
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 01, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.